Patent · US Expired

Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands

US5266698A · kind A · utility

60Cited by
3References
27Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 30, 1992
Grant dateNov 30, 1993
Priority date
Expiry dateApr 30, 2012

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

The present invention encompasses compounds of the formula: ##STR1## and the pharmaceutically acceptable non-toxic salts thereof wherein: where X represents hydrogen of lower alkyl; PA0 W represents an aryl group unsubstituted or substituted with various organic and inorganic substitutents; ##STR2## where A, B, C, D, and E represent carbon or nitrogen substituted with hydrogen or various organic and inorganic substituents; and PA0 n is 0, 1, or 2, Y, R.sub.3, R.sub.4, R.sub.12, and R.sub.13 are various organic and inorganic substituents. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine drugs, and enhancement of memory.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.